Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study
Key Points
This research aims to evaluate the effectiveness of second-line and subsequent therapies after first-line treatment failure in advanced hepatocellular carcinoma.
Multicenter prospective cohort study design
Focus on patients with advanced hepatocellular carcinoma
Assessment of therapies including lenvatinib and regorafenib
Evaluation of progression-free survival and overall survival metrics
Second-line lenvatinib treatment was associated with prolonged progression-free survival
Findings highlight the importance of optimizing sequential treatments for better patient outcomes
Abstract
In advanced HCC following 1L AtezoBev failure, 2L lenvatinib prolonged PFS, and 3L regorafenib improved OS. These findings underscore the need to optimize sequential systemic therapies to enhance survival.
Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study | Synapse